Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jean-Claude Eisenmann"'
Autor:
Michel Delforge, Leonard Minuk, Jean-Claude Eisenmann, Bertrand Arnulf, Letizia Canepa, Alberto Fragasso, Serge Leyvraz, Christian Langer, Yousef Ezaydi, Dan T. Vogl, Pilar Giraldo-Castellano, Sung-Soo Yoon, Charles Zarnitsky, Martine Escoffre-Barbe, Bernard Lemieux, Kevin Song, Nizar Jacques Bahlis, Shien Guo, Mara Silva Monzini, Annette Ervin-Haynes, Vanessa Houck, Thierry Facon
Publikováno v:
Haematologica, Vol 100, Iss 6 (2015)
We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethaso
Externí odkaz:
https://doaj.org/article/b6c5eb6be8a74816938b5ab8e0c80b69
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Supplementary tables 1 to 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b4211f3d6f9a4b9c4328e0c277e2ff
https://doi.org/10.1158/1078-0432.22472622
https://doi.org/10.1158/1078-0432.22472622
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Purpose:Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0665968cd1edf97628a1303b28c4bb
https://doi.org/10.1158/1078-0432.c.6528276
https://doi.org/10.1158/1078-0432.c.6528276
Autor:
Thierry Facon, Cyrille Hulin, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal, Eric G. Voog, Véronique Dorvaux, Jean-Claude Eisenmann, Damien Roos-Weil, Olivier Fitoussi, Jamile Frayfer, Catherine Humbrecht-Kraut, Olivier Decaux, Sophie Rigaudeau, Frédérique Kuhnowski, Sophie Cereja, Laurent Voillat, Fritz Offner, Anna Schmitt, Philippe Rodon, Jean Fontan, Marie-Lorraine Chrétien, Gérard Lepeu, Karim Belhadj-Merzoug, Marie-Odile Pétillon, Arnaud Jaccard, Murielle Roussel, Pascal Lenain, Pascal Bourquard, Jean-Valère Malfuson, Nathalie Meuleman, Carla Araujo, Mourad Tiab, Brigitte Kolb, Lionel Karlin, François Machuron, Alain Duhamel, Stéphanie Guidez, Valentine Richez, Guillemette Fouquet, Xavier Leleu
Supplementary Figure 1. Complementary survival curves for the whole cohort (n=30). (A) Event Free Survival (EFR); (B) Time to new treatment (TTNT); (C) Duration of response (DOR). Supplementary Figure 2. Progression Free Survival and Overall Survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a5b9305062769531748ccdd76584f24
https://doi.org/10.1158/1078-0432.22472625
https://doi.org/10.1158/1078-0432.22472625
Autor:
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal
Publikováno v:
Blood, Vol. 139, no. 18, p. 2747-2757 (2022)
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2eb889eef161542d4f0290176e12ee
https://doi.org/10.1182/blood.2021014635
https://doi.org/10.1182/blood.2021014635
Autor:
Sophie Cereja, Damien Roos-Weil, Laurent Voillat, Marie-Odile Petillon, Véronique Dorvaux, Marie-Lorraine Chretien, Nathalie Meuleman, Hervé Avet-Loiseau, Arthur Bobin, Olivier Fitoussi, Carla Araujo, Murielle Roussel, Eric Voog, Frédérique Kuhnowski, Intergroupe Francophone du Myelome Multiple, Jean Claude Eisenmann, Mourad Tiab, Catherine Humbrecht-Kraut, Thierry Facon, Jean-Valère Malfuson, Brigitte Kolb, Karim Belhadj-Merzoug, Philippe Rodon, Pascal Bourquard, Lionel Karlin, Olivier Decaux, Maeva Kyheng, Valentine Richez, Sophie Rigaudeau, Jamile Frayfer, Xavier Leleu, Philippe Moreau, Arnaud Jaccard, Alain Duhamel, Aurore Perrot, Pascal Lenain, Cyrille Hulin, Cécile Gruchet-Merouze, Jean Fontan, Anna Schmitt, Stéphanie Guidez, Fritz Offner
Publikováno v:
Leukemia
Leukemia, 2022, 36 (3), pp.881-884. ⟨10.1038/s41375-021-01415-x⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01415-x⟩
Leukemia, 2022, 36 (3), pp.881-884. ⟨10.1038/s41375-021-01415-x⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01415-x⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6cefeb2bdc7ab1443749447bd3dde7
https://hal.science/hal-03476700
https://hal.science/hal-03476700
Autor:
Hervé Tilly, Thierry Fest, Loic Ysebaert, Sylvie Glaisner, Guillaume Cartron, Rene-Olivier Casasnovas, Steven Le Gouill, Jean-Claude Eisenmann, Roch Houot, Marie-Hélène Delfau-Larue, Marie-Laure Boulland, Gilles Salles, Gian Matteo Pica, Franck Morschhauser, Asma Beldi-Ferchiou, François Lemonnier, Pierre Feugier, Luc Xerri, Pascal Godmer, Vincent Ribrag, Hervé Maisonneuve
Publikováno v:
Blood Advances
Blood Advances, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩
Blood Adv
Blood Advances, The American Society of Hematology, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩
Blood Advances, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩
Blood Adv
Blood Advances, The American Society of Hematology, 2020, 4 (14), pp.3217-3223. ⟨10.1182/bloodadvances.2020001955⟩
Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd46e191f95afc9eeae6e8aa9f49e79
https://www.hal.inserm.fr/inserm-03498367/document
https://www.hal.inserm.fr/inserm-03498367/document
Autor:
Xavier Troussard, Agnès Olivrie, Gandhi Damaj, Stephanie Noel, Jean-Claude Eisenmann, Olivier Hermine, Jérémie Riou, Sandrine Vaudaux, Patricia Validire-Charpy, Jean Gutnecht, Alain Devidas, Charlotte Petitdidier-Lionnet, Mohamed Touati, Stephanie Haiat, Vincent Levy, Fabienne Huysman, Eric Lippert, Aline Tanguy-Schmidt, Jehan Dupuis, Olivier Lambotte, Clara Mariette, Marouane Boubaya, Edouard Cornet, Pierre Feugier, Mathilde Hunault-Berger, Bertrand Joly, Stéphane Leprêtre, Jérôme Paillassa, Cécile Tomowiak, Kamel Ghomari, Willy Vaillant, Catherine Thieblemont, Mario Ojeda Uribe, Didier Decaudin, Bernard Drenou, Jean-Michel Karsenti
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2020, 10 (5), pp.62. ⟨10.1038/s41408-020-0328-z⟩
Blood Cancer Journal, 2020, 10 (5), pp.62. ⟨10.1038/s41408-020-0328-z⟩
Blood Cancer Journal, Vol 10, Iss 5, Pp 1-12 (2020)
Blood Cancer Journal, Nature Publishing Group, 2020, 10 (5), pp.62. ⟨10.1038/s41408-020-0328-z⟩
Blood Cancer Journal, 2020, 10 (5), pp.62. ⟨10.1038/s41408-020-0328-z⟩
Blood Cancer Journal, Vol 10, Iss 5, Pp 1-12 (2020)
In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc2018efa92d73138ccb93cf72fcb949
https://doi.org/10.1038/s41408-020-0328-z
https://doi.org/10.1038/s41408-020-0328-z
Autor:
Michel Attal, Frédérique Orsini-Piocelle, Herve Avet Loiseau, Lotfi Benboubker, Carla Araujo, Mourad Tiab, Sabine Brechignac, Eric Voog, Laurent Garderet, Karim Belhadj, Margaret Macro, Jean-Richard Eveillard, Brigitte Pegourie, Gerald Marit, Carine Chaleteix, Claire Mathiot, Arnaud Jaccard, Pascal Lenain, Benoit Berge, Bruno Royer, Anne-Marie Stoppa, Aurore Perrot, Mohamad Mohty, Xavier Leleu, Frédérique Kuhnowski, Murielle Roussel, Cyrille Hulin, Sylvie Glaisner, Ingrid Lafon, Martine Escoffre-Barbe, Olivier Allangba, Lionel Karlin, Marc Wetterwald, Philippe Moreau, Thierry Facon, Jean Claude Eisenmann, Eric Jourdan
Publikováno v:
Blood. 138:2753-2753
Background: The role of maintenance lenalidomide in myeloma, following autologous stem cell transplantation (ASCT) or not, is well established. However, 29% of patients discontinue the treatment with a median duration of less than 2 years with an inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72e44a8e41b4709f7f66a7fdb6ab9020
https://doi.org/10.1182/blood-2021-152136
https://doi.org/10.1182/blood-2021-152136
Autor:
Pascal Lenain, Sophie Rigaudeau, Cyrille Hulin, Jean Fontan, Catherine Humbrecht-Kraut, Marie-Lorraine Chretien, Hervé Avet-Loiseau, Frédérique Kuhnowski, Philippe Moreau, Jean Claude Eisenmann, Karim Belhadj-Merzoug, Murielle Roussel, Damien Roos-Weil, Marie-Odile Petillon, Alain Duhamel, Brigitte Kolb, Stéphanie Guidez, Jean Valère Malfuson, Véronique Dorvaux, Michel Attal, Anna Schmitt, Nathalie Meuleman, Valentine Richez, Sophie Cereja, François Machuron, Lionel Karlin, Olivier Decaux, Laurent Voillat, Thierry Facon, Fritz Offner, Mourad Tiab, Olivier Fitoussi, Pascal Bourquard, Guillemette Fouquet, Gérard Lepeu, Arnaud Jaccard, Xavier Leleu, Philippe Rodon, Jamile Frayfer, Carla Araujo, Eric Voog
Publikováno v:
Clinical cancer research, 25 (14
Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933390d52b3329309cf24d2e2512c25a
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/302977
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/302977